Gland Pharma Share Price: 27.0% CAGR in 3 Years as the Injectables Specialist Faces Divi’s Labs and Cipla
- November 11, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Gland Pharma Share Price: 27.0% CAGR in 3 Years as the Injectables Specialist Faces Divi’s Labs and Cipla
Gland Pharma previous close Rs 3,302.40. 3-year CAGR 27.0%. Up 2.0x since 9 Nov 2023. ROE 11.57%. Market cap Rs 54,476 crore.
Quick Answer
The Gland Pharma share price closed at Rs 3,302.40 on 9 November 2026, a compounded annual return of 27.0% over three years. That compares with Divi’s Laboratories at 49.0% and Cipla at 4.3%. The company has a market cap of Rs 54,476 crore and a P/E of 44.08 against an industry P/E of 40.13.
The Gland Pharma share price has delivered a strong return over three years, and that makes Gland Pharma one of the better-known specialists in the sector. The Hyderabad-based company focuses on injectable medicines and sells them to partners in regulated markets such as the United States and Europe.
This article compares that run with Divi’s Laboratories and Cipla. We calculate the three-year CAGR for all three and set the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Gland Pharma Share Price Returned in 3 Years?
The Gland Pharma stock closed at Rs 1,612.65 on 9 November 2023 and at Rs 3,302.40 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 2.05 lakh, which is a CAGR of 27.0%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Gland Pharma can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Gland Pharma share price has also followed the steady demand for sterile injectables, a category where entry barriers are higher than for ordinary tablets.
Gland Pharma vs Divi’s Laboratories and Cipla: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.
| Company | Close on 9 Nov 2023 | Previous close (9 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Divi’s Laboratories | Rs 3,498.50 | Rs 11,565.50 | 3.3x | 49.0% |
| Gland Pharma | Rs 1,612.65 | Rs 3,302.40 | 2.0x | 27.0% |
| Cipla | Rs 1,238.15 | Rs 1,403.80 | 1.1x | 4.3% |
The Gland Pharma stock ranks second of the three at 27.0%. It sits ahead of Cipla (4.3%). The company ahead is Divi’s Laboratories (49.0%). Divi’s Laboratories leads the group, followed by Gland Pharma and then Cipla. Gland Pharma is the smallest of the three by market cap, which makes its yearly return a notable result for a mid-sized company.
Look at the Gland Pharma share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Divi’s Laboratories | Rs 3,07,147 crore | 91.33 | 40.13 | 15.32% | 0.00 |
| Cipla | Rs 1,13,589 crore | 39.81 | 40.71 | 8.18% | 0.02 |
| Gland Pharma | Rs 54,476 crore | 44.08 | 40.13 | 11.57% | 0.02 |
By market cap, Divi’s Laboratories is the largest of the group at Rs 3,07,147 crore, while the Gland Pharma stock stands at Rs 54,476 crore, about 18% of that size. On earnings, Gland Pharma shares trade at a P/E of 44.08 against an industry P/E of 40.13, a premium of about 10%, which signals that the market expects faster earnings growth. Peer multiples are Divi’s Laboratories at 91.33 and Cipla at 39.81.
Return on equity is 11.57% for the Gland Pharma stock, which ranks second among the three, and debt to equity stands at 0.02. Trailing EPS is Rs 74.90. Specialist manufacturers are valued on the quality of their customer relationships and plant compliance, so the P/E should be read next to return on equity and growth.
What Is Driving the Gland Pharma Stock?
Gland Pharma makes injectables such as vials, ampoules and pre-filled syringes. It works with partners that sell under their own brands, and this contract model spreads risk across many products and customers.
The company has widened its range through additional capacity and by adding complex injectables, which can carry better margins. Its balance sheet carries almost no debt, which gives it room to invest.
Followers of the Gland Pharma share price usually track the number of new product approvals, customer concentration, regulatory inspections and the contribution from its Indian and overseas units.
How the Established Players Stack Up
Divi’s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients and custom synthesis products for global drug companies. It compounded at 49.0% a year, on a market cap of Rs 3,07,147 crore and an ROE of 15.32%.
Cipla is a Mumbai-based drug maker with strength in respiratory medicines and a significant presence in India, the United States and South Africa. It compounded at 4.3% a year, on a market cap of Rs 1,13,589 crore and an ROE of 8.18%.
What Should Investors Track Next?
Three things are worth watching on the Gland Pharma share price. First, the pace of new injectable approvals. Second, plant inspection outcomes. Third, margins as the product mix changes.
At a P/E of 44, the stock trades slightly above the industry P/E of 40, and its debt to equity of 0.02 is almost nil. Regulatory outcomes can move quarterly numbers, so follow results closely.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Gland Pharma stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Gland Pharma share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Gland Pharma share price and compare pharma stocks live.
An Injectables Specialist With Almost No Debt
The Gland Pharma share price compounded at 27.0% a year over three years, ahead of Cipla at 4.3% and behind Divi’s Laboratories at 49.0%. Its ROE is 11.57% and its debt is almost nil.
Divi’s Laboratories brings a faster return at a higher multiple, while Cipla brings scale and a respiratory focus. The choice depends on which business model you prefer.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Gland Pharma share price today?
Ans. Gland Pharma closed at Rs 3,302.40 on 9 November 2026, according to NSE data. It has a market cap of Rs 54,476 crore and a P/E of 44.08. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Gland Pharma stock?
Ans. Gland Pharma delivered a price CAGR of 27.0% over three years, moving from Rs 1,612.65 on 9 November 2023 to Rs 3,302.40 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Gland Pharma better than Cipla?
Ans. Gland Pharma delivered a higher three-year CAGR at 27.0% than Cipla at 4.3%. Cipla is larger by market cap at Rs 1,13,589 crore against Rs 54,476 crore, while Gland Pharma has a higher ROE at 11.57% against 8.18%. The better choice depends on your view of each business.
What does Gland Pharma do?
Ans. Gland Pharma is a Hyderabad-based maker of injectable medicines that supplies partners across regulated and emerging markets.
Is the Gland Pharma stock debt free?
Ans. The debt to equity ratio of the Gland Pharma stock is 0.02 and its return on equity is 11.57%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Gland Pharma expensive compared with the industry?
Ans. Gland Pharma trades at a P/E of 44.08 against an industry P/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Divi’s Laboratories delivered the highest three-year CAGR at 49.0%, followed by Gland Pharma at 27.0%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.
